- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02892760
Clinical Algorithm for Post-Stroke Gait Training With C-Brace
October 8, 2021 updated by: Gerard Francisco, The University of Texas Health Science Center, Houston
The purpose of this study is to develop a clinical algorithmic-based evaluation and treatment approach for C-Brace for use by persons with hemiparesis or hemiplegia due to stroke.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- TIRR Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 - 65 years
- Diagnosis of hemiparesis or hemiplegia following stroke
- Presence of abnormal walking pattern
- Poor knee control during stance phase
- Cognitive ability to (or care provider) manage daily charging of battery
- Cognitive ability to follow commands
- Hip flexor muscle strength grade 3 or greater or the ability to perform reciprocal gait using compensatory patterns
Exclusion Criteria:
- Weight > 275 lbs. (Includes body weight and weight of heaviest object carried)
- Less than 2° of ankle motion
- Severe spasticity of the quadriceps (MAS >3) and/or uncontrolled spasticity of the quadriceps
- Severe spasticity of other lower limb muscles (MAS >3)
- Fixed genuvalgum exceeding 10° beyond anatomic neutral valgum
- Any fixed genuvarum exceeding anatomic neutral varum.
- Hip or knee flexion contractures greater than 10°
- Presence of chronic obstructive pulmonary disease (COPD)
- Chronic heart failure - New York Heart Association (NYHA) stages 3 and 4
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: with C-brace
C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
|
C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gait Quality as Indicated by Joint Excursion as Assessed by Kinematic Analysis
Time Frame: week 5
|
During the 10 Meter Walk Test (10MWT), infrared light emitting diode markers will be attached to bilateral lower extremities.
The marker data will be recorded using the Northern Digital Inc (NDI) Optotrak Certus motion capture system.
Marker data will be processed using custom Matlab program to determine lower extremity joint excursion.
Joint excursion is the range of motion of a particular joint, and the range of motion is reported in degrees.
After stroke, one side of the body is affected, and joint excursion for various joint angles (of hip, knee, and ankle) are reported for both sides of the body (affected side of body and unaffected side of body).
|
week 5
|
Gait Quality as Indicated by Joint Excursion as Assessed by Kinematic Analysis
Time Frame: week 9
|
During the 10 Meter Walk Test (10MWT), infrared light emitting diode markers will be attached to bilateral lower extremities.
The marker data will be recorded using the NDI Optotrak Certus motion capture system.
Marker data will be processed using custom Matlab program to determine lower extremity joint excursion.
Joint excursion is the range of motion of a particular joint, and the range of motion is reported in degrees.
After stroke, one side of the body is affected, and joint excursion for various joint angles (of hip, knee, and ankle) are reported for both sides of the body (affected side of body and unaffected side of body).
|
week 9
|
Change in Muscle Function as Indicated by EMG Amplitude Assessed by Surface Electromyography (sEMG)
Time Frame: week 5
|
Bipolar surface electrodes will be placed on the bilateral major leg muscles to record electromyography (1000Hz, Motion Labs 16-Channel EMG System).
The EMG amplitude (in volts) will be calculated over the whole gait cycle during the 10 Meter Walk Test (10MWT), in which the participant walks 10 meters.
After stroke, one side of the body is affected, and data for various muscles are reported for both sides of the body (affected side of body and unaffected side of body).
|
week 5
|
Change in Muscle Function as Indicated by EMG Amplitude Assessed by Surface Electromyography (sEMG)
Time Frame: week 9
|
Bipolar surface electrodes will be placed on the bilateral major leg muscles to record electromyography (1000Hz, Motion Labs 16-Channel EMG System).
The EMG amplitude (in volts) will be calculated over the whole gait cycle during the 10 Meter Walk Test (10MWT), in which the participant walks 10 meters.
After stroke, one side of the body is affected, and data for various muscles are reported for both sides of the body (affected side of body and unaffected side of body).
|
week 9
|
Metabolic Expenditure During Walking
Time Frame: week 5
|
Change in metabolic expenditure during walking will be indicated by energy expenditure.
Energy Expenditure will be measured by the K4 b2 Cosmed as follows: Oxygen cost will be calculated from oxygen consumption as the product of gait speed and body weight.
Oxygen consumption will be collected on a breath-by-breath basis measured by a portable metabolic system (K4 b2 Cosmed).
Prior to the testing, the system will be calibrated using room air and reference gas mixture.
During the testing, the subject will wear a face mask and a heart rate monitor at all times and will be asked to breathe normally.
|
week 5
|
Metabolic Expenditure During Walking
Time Frame: week 9
|
Change in metabolic expenditure during walking will be indicated by energy expenditure.
Energy Expenditure will be measured by the K4 b2 Cosmed as follows: Oxygen cost will be calculated from oxygen consumption as the product of gait speed and body weight.
Oxygen consumption will be collected on a breath-by-breath basis measured by a portable metabolic system (K4 b2 Cosmed).
Prior to the testing, the system will be calibrated using room air and reference gas mixture.
During the testing, the subject will wear a face mask and a heart rate monitor at all times and will be asked to breathe normally.
|
week 9
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Score on the Timed Up and Go Test
Time Frame: week 0
|
Assesses mobility, balance, walking ability, and fall risk in older adults.
The test measures the time it takes the subject to perform a sit to stand from a chair with arms, walk to a mark on the ground 10 feet away and return to the seated position in the chair with arms.
This test has been used in assessing stroke recovery with high reliability and validity.
|
week 0
|
Score on the Timed Up and Go Test
Time Frame: week 5
|
Assesses mobility, balance, walking ability, and fall risk in older adults.
The test measures the time it takes the subject to perform a sit to stand from a chair with arms, walk to a mark on the ground 10 feet away and return to the seated position in the chair with arms.
This test has been used in assessing stroke recovery with high reliability and validity.
|
week 5
|
Score on the Timed Up and Go Test
Time Frame: week 9
|
Assesses mobility, balance, walking ability, and fall risk in older adults.
The test measures the time it takes the subject to perform a sit to stand from a chair with arms, walk to a mark on the ground 10 feet away and return to the seated position in the chair with arms.
This test has been used in assessing stroke recovery with high reliability and validity.
|
week 9
|
Mental State as Assessed by the Folstein Mini Mental State Examination (MMSE)
Time Frame: week 0
|
Mini Mental State Examination provides information about orientation, attention, learning, calculation, delayed recall, and construction.
Several studies report acceptable validity of MMSE as a screening instrument and its relationship to functional outcome in stroke population.
Total score ranges from 0 to 30, with a higher score indicating a better outcome.
|
week 0
|
Mental State as Assessed by the Folstein Mini Mental State Examination (MMSE)
Time Frame: week 9
|
Mini Mental State Examination provides information about orientation, attention, learning, calculation, delayed recall, and construction.
Several studies report acceptable validity of MMSE as a screening instrument and its relationship to functional outcome in stroke population.
Total score ranges from 0 to 30, with a higher score indicating a better outcome.
|
week 9
|
Change in Hip Flexors Strength as Assessed by Dynamometry
Time Frame: week 0, week 9
|
Muscle strength will be measured and quantified by using dynamometers on major bilateral lower limb muscles such as hip flexors.
|
week 0, week 9
|
Change in Hip Extensors Strength as Assessed by Dynamometry
Time Frame: week 0, week 9
|
Muscle strength will be measured and quantified by using dynamometers on major bilateral lower limb muscles such as hip extensors.
|
week 0, week 9
|
Change in Hip Abductors Strength as Assessed by Dynamometry
Time Frame: week 0, week 9
|
Muscle strength will be measured and quantified by using dynamometers on major bilateral lower limb muscles such as hip abductors.
|
week 0, week 9
|
Change in Hip Adductors Strength as Assessed by Dynamometry
Time Frame: week 0, week 9
|
Muscle strength will be measured and quantified by using dynamometers on major bilateral lower limb muscles such as hip adductors.
|
week 0, week 9
|
Change in Knee Flexors Strength as Assessed by Dynamometry
Time Frame: week 0, week 9
|
Muscle strength will be measured and quantified by using dynamometers on major bilateral lower limb muscles such as knee flexors.
|
week 0, week 9
|
Change in Knee Extensors Strength as Assessed by Dynamometry
Time Frame: week 0, week 9
|
Muscle strength will be measured and quantified by using dynamometers on major bilateral lower limb muscles such as knee extensors.
|
week 0, week 9
|
Change in Ankle Dorsiflexors Strength as Assessed by Dynamometry
Time Frame: week 0, week 9
|
Muscle strength will be measured and quantified by using dynamometers on major bilateral lower limb muscles such as ankle dorsiflexors.
|
week 0, week 9
|
Change in Ankle Plantarflexors. Strength as Assessed by Dynamometry
Time Frame: week 0, week 9
|
Muscle strength will be measured and quantified by using dynamometers on major bilateral lower limb muscles such as ankle plantarflexors.
|
week 0, week 9
|
Number of Participants With Bilateral Hip Range of Motion Within Normal Limits as Assessed by Goniometry
Time Frame: week 0
|
Range of motion will be measured on bilateral hip using goniometry (goniometry is the use of a device called a goniometer to measure range of motion of a joint in degrees).
After stroke, one side of the body is affected.
For each participant, the range of motion of their affected hip will be measured and also the range of motion of their other hip (the unaffected hip) will be measured [it is possible that a participant will have a range of motion within normal limits on both hip sides (affected hip and unaffected hip)].
|
week 0
|
Number of Participants With Bilateral Hip Range of Motion Within Normal Limits as Assessed by Goniometry
Time Frame: week 9
|
Range of motion will be measured on bilateral hip using goniometry (goniometry is the use of a device called a goniometer to measure range of motion of a joint in degrees).
After stroke, one side of the body is affected.
For each participant, the range of motion of their affected hip will be measured and also the range of motion of their other hip (the unaffected hip) will be measured [it is possible that a participant will have a range of motion within normal limits on both hip sides (affected hip and unaffected hip)].
|
week 9
|
Number of Participants With Knee Joint Range of Motion Within Normal Limits as Assessed by Goniometry
Time Frame: week 0
|
Range of motion will be measured on knee joints using goniometry (goniometry is the use of a device called a goniometer to measure range of motion of a joint in degrees).
After stroke, one side of the body is affected.
For each participant, the range of motion of their affected knee will be measured and also the range of motion of their other knee (the unaffected knee) will be measured [it is possible that a participant will have a range of motion within normal limits for both knees (affected knee and unaffected knee)].
|
week 0
|
Number of Participants With Knee Joint Range of Motion Within Normal Limits as Assessed by Goniometry
Time Frame: week 9
|
Range of motion will be measured on knee joints using goniometry (goniometry is the use of a device called a goniometer to measure range of motion of a joint in degrees).
After stroke, one side of the body is affected.
For each participant, the range of motion of their affected knee will be measured and also the range of motion of their other knee (the unaffected knee) will be measured [it is possible that a participant will have a range of motion within normal limits for both knees (affected knee and unaffected knee)].
|
week 9
|
Number of Participants With Ankle Joint Range of Motion Within Normal Limits as Assessed by Goniometry
Time Frame: week 0
|
Range of motion will be measured on ankle joints using goniometry (goniometry is the use of a device called a goniometer to measure range of motion of a joint in degrees).
After stroke, one side of the body is affected.
For each participant, the range of motion of their affected ankle will be measured and also the range of motion of their other ankle (the unaffected ankle) will be measured [it is possible that a participant will have a range of motion within normal limits for both ankles (affected ankle and unaffected ankle)].
|
week 0
|
Number of Participants With Ankle Joint Range of Motion Within Normal Limits as Assessed by Goniometry
Time Frame: week 9
|
Range of motion will be measured on ankle joints using goniometry (goniometry is the use of a device called a goniometer to measure range of motion of a joint in degrees).
After stroke, one side of the body is affected.
For each participant, the range of motion of their affected ankle will be measured and also the range of motion of their other ankle (the unaffected ankle) will be measured [it is possible that a participant will have a range of motion within normal limits for both ankles (affected ankle and unaffected ankle)].
|
week 9
|
Motor Impairment as Determined by the Fugl-Meyer Assessment
Time Frame: week 0
|
The Fugl-Meyer Assessment evaluates and measures recovery of movement in individual post stroke.
The Fugl-Meyer has been used in both clinical and research settings and is one of the most widely used quantitative measures of motor impairment.
It uses an ordinal scale for scoring of 17 items for the lower limb component and 7 items on the balance component, for a total of 24 items.
Each of the 24 items is scored as 0 (cannot perform), 1 (can perform partially), or 2 (can perform fully), with a total score ranging from 0 to 48, with a higher score indicating less impairment.
|
week 0
|
Motor Impairment as Determined by the Fugl-Meyer Assessment
Time Frame: week 9
|
The Fugl-Meyer Assessment evaluates and measures recovery of movement in individual post stroke.
The Fugl-Meyer has been used in both clinical and research settings and is one of the most widely used quantitative measures of motor impairment.
It uses an ordinal scale for scoring of 17 items for the lower limb component and 7 items on the balance component, for a total of 24 items.
Each of the 24 items is scored as 0 (cannot perform), 1 (can perform partially), or 2 (can perform fully), with a total score ranging from 0 to 48, with a higher score indicating less impairment.
|
week 9
|
Spasticity as Assessed by the Modified Ashworth Scale (MAS)
Time Frame: week 0
|
This test measures spasticity in patients with lesions of the Central Nervous System by testing resistance to passive movement about a joint with varying degrees of velocity.
Scores range from 0-4, with 0 indicating normal muscle tone and 4 indicating very high spasticity.
The investigators will measure spasticity in lower limbs.
|
week 0
|
Spasticity as Assessed by the Modified Ashworth Scale (MAS)
Time Frame: week 9
|
This test measures spasticity in patients with lesions of the Central Nervous System by testing resistance to passive movement about a joint with varying degrees of velocity.
Scores range from 0-4, with 0 indicating normal muscle tone and 4 indicating very high spasticity.
The investigators will measure spasticity in lower limbs.
|
week 9
|
Static Balance as Assessed by the Berg Balance Scale (BBS)
Time Frame: week 0
|
A 14-item objective measure designed to assess static balance and fall risk in adult populations, with a total score range of 0 to 56 (higher scores represent better functional outcome).
This test has been widely used to measure functional recovery in stroke patients with high reliability.
|
week 0
|
Static Balance as Assessed by the Berg Balance Scale (BBS)
Time Frame: week 9
|
A 14-item objective measure designed to assess static balance and fall risk in adult populations, with a total score range of 0 to 56 (higher scores represent better functional outcome).
This test has been widely used to measure functional recovery in stroke patients with high reliability.
|
week 9
|
Gait Speed as Assessed by the 10 Meter Walk Test (10MWT)
Time Frame: week 0
|
Measure of gait speed.
Subjects will walk a total of 14 meters at their preferred walking speed and at a fast pace.
The test measures the time it takes the subject to complete the middle 10 meters of the walk.
|
week 0
|
Gait Speed as Assessed by the 10 Meter Walk Test (10MWT)
Time Frame: week 5
|
Measure of gait speed.
Subjects will walk a total of 14 meters at their preferred walking speed and at a fast pace.
The test measures the time it takes the subject to complete the middle 10 meters of the walk.
|
week 5
|
Gait Speed as Assessed by the 10 Meter Walk Test (10MWT)
Time Frame: week 9
|
Measure of gait speed.
Subjects will walk a total of 14 meters at their preferred walking speed and at a fast pace.
The test measures the time it takes the subject to complete the middle 10 meters of the walk.
|
week 9
|
Aerobic Capacity as Assessed by Peak VO₂ Per Kilogram Body Weight During the Six-minute Walk Test (6MWT)
Time Frame: week 0
|
The participant will perform the 6MWT, in which the participant will walk as far as possible in six minutes.
During the 6MWT, the peak volume of oxygen consumed per minute (peak VO₂) will be measured by a portable metabolic system.
Data are reported as peak volume of oxygen (in milliliters) consumed per kilogram bodyweight per minute per meter walked [milliliters/kilogram/minute/meter (mL/kg/min/m)].
|
week 0
|
Aerobic Capacity as Assessed by Peak VO₂ Per Kilogram Body Weight During the Six-minute Walk Test (6MWT)
Time Frame: week 5
|
The participant will perform the 6MWT, in which the participant will walk as far as possible in six minutes.
During the 6MWT, the peak volume of oxygen consumed per minute (peak VO₂) will be will be measured by a portable metabolic system.
Data are reported as peak volume of oxygen (in milliliters) consumed per kilogram bodyweight per minute per meter walked [milliliters/kilogram/minute/meter (mL/kg/min/m)].
|
week 5
|
Aerobic Capacity as Assessed by Peak VO₂ Per Kilogram Body Weight During the Six-minute Walk Test (6MWT)
Time Frame: week 9
|
The participant will perform the 6MWT, in which the participant will walk as far as possible in six minutes.
During the 6MWT, the peak volume of oxygen consumed per minute (peak VO₂) will be will be measured by a portable metabolic system.
Data are reported as peak volume of oxygen (in milliliters) consumed per kilogram bodyweight per minute per meter walked [milliliters/kilogram/minute/meter (mL/kg/min/m)].
|
week 9
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 13, 2017
Primary Completion (Actual)
January 8, 2019
Study Completion (Actual)
January 8, 2019
Study Registration Dates
First Submitted
August 2, 2016
First Submitted That Met QC Criteria
September 1, 2016
First Posted (Estimate)
September 8, 2016
Study Record Updates
Last Update Posted (Actual)
November 8, 2021
Last Update Submitted That Met QC Criteria
October 8, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-16-0031
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemiparesis Due to Stroke
-
Orthocare Innovations, LLCNational Institute on Disability, Independent Living, and Rehabilitation...RecruitingStroke | Upper Limb Amputation | Upper Limb Weakness Due to Central Neurologic Injury | Upper Limb Weakness Due to Peripheral Neurologic Injury | Upper Limb Weakness Due to Nerve Reconstruction | Upper Limb Weakness Due to Tendon Transfer SurgeryUnited States
-
Prehospital Center, Region ZealandNot yet recruitingDrowning | Drowning, Near | Submersion | Submersion - Accidental | Submersion or Drowning Due to Being Washed Overboard | Submersion or Drowning Due to Being Thrown Overboard | Submersion or Drowning Due to Ship Sinking, Water Skier Injured | Submersion or Drowning Due to Boat Submerging, Swimmer... and other conditionsDenmark
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedPoor Metabolizer Due to Cytochrome P450 CYP2C9 Variant | Poor Metabolizer Due to Cytochrome p450 CYP2C19 VariantBrazil
-
Qazvin University Of Medical SciencesCompletedPain Due to Propofol Injection | Hemodynamic Changes Due to Propofol InjectionIran, Islamic Republic of
-
The University of The West IndiesRecruiting
-
Cardiff UniversityCompletedPlatelet Dysfunction Due to AspirinUnited Kingdom
-
Northwell HealthWithdrawnPlatelet Dysfunction Due to Drugs
-
George Washington UniversityCompletedPlatelet Dysfunction Due to AspirinUnited States
-
The University of The West IndiesCompletedPlatelet Dysfunction Due to DrugsTrinidad and Tobago
-
The University of The West IndiesCompletedPlatelet Dysfunction Due to DrugsTrinidad and Tobago
Clinical Trials on C-Brace
-
Shirley Ryan AbilityLabOtto Bock Healthcare Products GmbHActive, not recruitingArthritis | Spinal Cord Injuries | Poliomyelitis | Post-polio Syndrome | Lower Motor Neurone LesionUnited States
-
Shirley Ryan AbilityLabOtto Bock Healthcare Products GmbHRecruiting
-
Otto Bock France SNCEVAMEDCompleted
-
Otto Bock Healthcare Products GmbHRecruiting
-
Seoul National University HospitalCompleted
-
St. Justine's HospitalActive, not recruitingScoliosis | Idiopathic ScoliosisCanada
-
University of California, Los AngelesRecruitingSpinal Fusion | Chronic Lower Back PainUnited States
-
Barbara ŁysońCompleted
-
Seoul National University HospitalCompletedNeuromuscular ScoliosisKorea, Republic of
-
OrthoCarolina Research Institute, Inc.CompletedHip Dislocation, Congenital | Congenital Deformity of Hip JointUnited States